Reviewing Enanta Pharmaceuticals (NASDAQ:ENTA) and Cosmos Health (NASDAQ:COSM)

Enanta Pharmaceuticals (NASDAQ:ENTA) and Cosmos Health (NASDAQ:COSM) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, risk, institutional ownership, earnings, profitability, valuation and analyst recommendations.

Valuation & Earnings

This table compares Enanta Pharmaceuticals and Cosmos Health”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enanta Pharmaceuticals	$65.32 million	6.18	-$81.89 million	($2.59)	-5.36
Cosmos Health	$65.27 million	0.31	-$19.15 million	($0.64)	-0.51

Cosmos Health has lower revenue, but higher earnings than Enanta Pharmaceuticals. Enanta Pharmaceuticals is trading at a lower price-to-earnings ratio than Cosmos Health, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Enanta Pharmaceuticals and Cosmos Health’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Enanta Pharmaceuticals	-89.56%	-64.04%	-20.22%
Cosmos Health	-30.41%	-52.85%	-17.87%

Institutional and Insider Ownership

95.0% of Enanta Pharmaceuticals shares are owned by institutional investors. Comparatively, 12.6% of Cosmos Health shares are owned by institutional investors. 11.5% of Enanta Pharmaceuticals shares are owned by company insiders. Comparatively, 26.2% of Cosmos Health shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of current ratings and price targets for Enanta Pharmaceuticals and Cosmos Health, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enanta Pharmaceuticals	1	0	7	0	2.75
Cosmos Health	1	0	0	0	1.00

Enanta Pharmaceuticals presently has a consensus price target of $20.29, suggesting a potential upside of 46.06%. Given Enanta Pharmaceuticals’ stronger consensus rating and higher possible upside, analysts clearly believe Enanta Pharmaceuticals is more favorable than Cosmos Health.

Volatility and Risk

Enanta Pharmaceuticals has a beta of 0.96, indicating that its stock price is 4% less volatile than the S&P 500. Comparatively, Cosmos Health has a beta of 4.83, indicating that its stock price is 383% more volatile than the S&P 500.

Summary

Cosmos Health beats Enanta Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts.

About Cosmos Health

Cosmos Health Inc. manufactures, develops, and trades branded nutraceutical products in Greece, the United Kingdom, Croatia, Bulgaria, Cayman Islands, and Cyprus. It offers medicines, OTC medicines, nutraceutical products, vitamins, minerals and dietary, health care products, medical devices, baby products, and others under the Sky Premium Life and Mediterranation brand names. The company serves wholesale distributors and other healthcare providers, such as clinics, government agencies, independent retail and specialty pharmacies and independent specialty distributors. It sells its products through independent wholesale distributors. Cosmos Health Inc. was incorporated in 2009 and is headquartered in Chicago, Illinois.